Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Phase 1

Completed

Conditions: Prostatic Neoplasms
Prostate Cancer

Interventions: Drug: Panobinostat
Drug: Bicalutamide

First Posted Date: 2009-04-09

Last Posted Date: 2018-02-07

Lead Sponsor: NYU Langone Health

Target Recruit Count: 52

Registration Number: NCT00878436

Locations: 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
North Shore University Hospital-Monter Cancer Center, Lake Success, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States

and more 1 locations

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer
Prostatic Neoplasms

Interventions: Drug: Docetaxel
Drug: Imatinib Mesylate

First Posted Date: 2009-03-13

Last Posted Date: 2016-06-30

Lead Sponsor: NYU Langone Health

Target Recruit Count: 24

Registration Number: NCT00861471

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Clinical Cancer Center, New York, New York, United States
🇺🇸
NYU Tisch Hospital, New York, New York, United States

Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer

Phase 2

Completed

Conditions: Gastric Cancer
Stomach Cancer

First Posted Date: 2009-03-09

Last Posted Date: 2016-03-11

Lead Sponsor: NYU Langone Health

Target Recruit Count: 28

Registration Number: NCT00858338

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States
🇺🇸
NYU Tisch Hospital, New York, New York, United States

Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer
Stomach Cancer

Interventions: Drug: Cetuximab
Drug: Irinotecan
Drug: Cisplatin
Procedure: Surgery
Drug: 5-FU
Radiation: Radiation

First Posted Date: 2009-03-06

Last Posted Date: 2015-12-07

Lead Sponsor: NYU Langone Health

Target Recruit Count: 30

Registration Number: NCT00857246

Locations: 🇺🇸
NYU Cancer Center, New York, New York, United States

Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids

Completed

Conditions: Postoperative Cognitive Dysfunction
Mild Cognitive Impairment

First Posted Date: 2009-02-25

Last Posted Date: 2016-03-17

Lead Sponsor: NYU Langone Health

Target Recruit Count: 41

Registration Number: NCT00850928

Locations: 🇺🇸
NYU School of Medicine, New York City, New York, United States

Cancer Screening and Prevention Program for High Risk Women

Completed

Conditions: Ovarian Cancer
Breast Cancer

First Posted Date: 2009-02-23

Last Posted Date: 2020-05-06

Lead Sponsor: NYU Langone Health

Target Recruit Count: 1452

Registration Number: NCT00849199

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States
🇺🇸
NYU Tisch Hospital, New York, New York, United States

Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers

Phase 2

Terminated

Conditions: Gastric Cancer
Esophageal Cancer
Gastric Adenocarcinoma

Interventions: Drug: Irinotecan
Drug: Cisplatin
Procedure: Surgery
Drug: Floxuridine
Drug: Capecitabine

First Posted Date: 2009-02-20

Last Posted Date: 2018-01-08

Lead Sponsor: NYU Langone Health

Target Recruit Count: 8

Registration Number: NCT00848783

Locations: 🇺🇸
Norris Cancer Center, Los Angeles, California, United States
🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Doxil
Drug: Bevacizumab (Avastin)

First Posted Date: 2009-02-19

Last Posted Date: 2019-09-30

Lead Sponsor: NYU Langone Health

Target Recruit Count: 15

Registration Number: NCT00846612

Locations: 🇺🇸
Univ. of New Mexico cancer research and treatment center, Albuquerque, New Mexico, United States
🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States

and more 1 locations

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide (Revlimid)
Drug: Melphalan
Drug: Dexamethasone

First Posted Date: 2009-02-13

Last Posted Date: 2017-07-19

Lead Sponsor: NYU Langone Health

Target Recruit Count: 8

Registration Number: NCT00843310

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States
🇺🇸
NYU Tisch Hospital, New York, New York, United States

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Phase 2

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Gleevec/Paclitaxel

First Posted Date: 2009-02-10

Last Posted Date: 2012-11-19

Lead Sponsor: NYU Langone Health

Target Recruit Count: 14

Registration Number: NCT00840450

Locations: 🇺🇸
NYU cancer center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy